Sooyeon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sooyeon Lee has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Jan Tuckermann
Institute of Comparative Molecular Endocrinology, Ulm University, Ulm, Baden-Württemberg, Germany
5 shared publications Kevin Leclerc
Department of Orthopaedic Surgery, NYU Robert I. Grossman School of Medicine, New York, USA
3 shared publications- Mubashir Ahmad
Institute of Orthopedic Research and Biomechanics, Ulm University Medical Center, Germany
3 shared publications - Philipp Leucht
NYU Langone Orthopedics, New York University Langone Medical Center, New York, United States
3 shared publications - Anita Ignatius
Institute of Orthopedic Research and Biomechanics, Ulm University Medical Center, Germany
2 shared publications Ann-Kristin Dorn
Institute of Molecular Endocrinology and Physiology, Ulm University, Ulm, Germany
2 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Elsevier in SSRN Electronic Journal
Targeting CDC42 Activity Attenuates Skeletal Degeneration upon Aging
Age-associated bone loss reflects an imbalance between mesenchymal-lineage-dependent bone formation and hematopoietic-lineage-dependent bone resorption. Osteoblast-lineage cells, including bone-lining cells and osteocytes, arise from mesenchymal stem/progenitor cells (MSPCs), whereas osteoclasts originate from hematopoietic progenitors. CDC42, a small Rho GTPase regulating actin dynamics and cellular polarity, has been reported to become deregulated in several aging stem-cell compartments and disrupts cytoskeletal organization. We tested whether a brief mid-life intervention targeting CDC42 could produce a skeletal phenotype detectable at advanced age and whether this phenotype involved coordinated changes across these two stem-cell-derived bone-remodeling lineages. Thirteen-month-old mice received the CDC42 inhibitor CASIN for four consecutive days and were analysed at 24 months. Remarkably, skeletal differences were detected approximately 11 months after the intervention. The µCT showed higher trabecular bone volume and greater cortical thickness in CASIN-treated aged mice than in aged vehicle-treated controls. CASIN treatment was associated with higher numbers of Osterix-positive bone-lining cells, lower osteocyte density, and osteocyte nuclear morphology shifted toward the young reference state in aged mice. At the 24-month endpoint, aged vehicle-treated MSPCs displayed fragmented F-actin networks, reduced MYO6–F-actin colocalization and altered TOMM20-defined mitochondrial morphology, whereas MSPCs from CASIN-treated aged mice showed improved cytoskeletal and mitochondrial organization. These readouts are interpreted as an endpoint-associated MSPC state rather than evidence of continuous CDC42 inhibition throughout the 11-month interval. The late phenotype also involved the hematopoietic lineage. CASIN-treated aged mice showed lower LT-HSC, monocyte and granulocyte numbers than aged vehicle-treated controls. Serum TRAcP5b and endosteal TRAP staining further indicated reduced osteoclast-associated bone resorption and osteoclast abundance. In aged human MSPCs, CASIN improved F-actin organization and osteogenic differentiation potential. In summary, a brief mid-life CASIN pulse was associated approximately 11 months later with long-term attenuation of age-associated skeletal degeneration, accompanied by coordinated changes across the mesenchymal osteogenic and HSC-derived myeloid/osteoclast lineages. Direct cytoskeletal and mitochondrial evidence was obtained in MSPCs, whereas the hematopoietic and osteoclast findings indicate broader multi-lineage effects. These data identify CDC42-sensitive responses across the two major stem-cell-derived compartments of the bone marrow as a potential determinant of skeletal aging.
- 3 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTargeting CDC42 Activity Attenuates Skeletal Degeneration upon Aging
Age-associated bone loss reflects an imbalance between mesenchymal-lineage-dependent bone formation and hematopoietic-lineage-dependent bone resorption. Osteoblast-lineage cells, including bone-lining cells and osteocytes, arise from mesenchymal stem/progenitor cells (MSPCs), whereas osteoclasts originate from hematopoietic progenitors. CDC42, a small Rho GTPase regulating actin dynamics and cellular polarity, has been reported to become deregulated in several aging stem-cell compartments and disrupts cytoskeletal organization. We tested whether a brief mid-life intervention targeting CDC42 could produce a skeletal phenotype detectable at advanced age and whether this phenotype involved coordinated changes across these two stem-cell-derived bone-remodeling lineages. Thirteen-month-old mice received the CDC42 inhibitor CASIN for four consecutive days and were analysed at 24 months. Remarkably, skeletal differences were detected approximately 11 months after the intervention. The µCT showed higher trabecular bone volume and greater cortical thickness in CASIN-treated aged mice than in aged vehicle-treated controls. CASIN treatment was associated with higher numbers of Osterix-positive bone-lining cells, lower osteocyte density, and osteocyte nuclear morphology shifted toward the young reference state in aged mice. At the 24-month endpoint, aged vehicle-treated MSPCs displayed fragmented F-actin networks, reduced MYO6–F-actin colocalization and altered TOMM20-defined mitochondrial morphology, whereas MSPCs from CASIN-treated aged mice showed improved cytoskeletal and mitochondrial organization. These readouts are interpreted as an endpoint-associated MSPC state rather than evidence of continuous CDC42 inhibition throughout the 11-month interval. The late phenotype also involved the hematopoietic lineage. CASIN-treated aged mice showed lower LT-HSC, monocyte and granulocyte numbers than aged vehicle-treated controls. Serum TRAcP5b and endosteal TRAP staining further indicated reduced osteoclast-associated bone resorption and osteoclast abundance. In aged human MSPCs, CASIN improved F-actin organization and osteogenic differentiation potential. In summary, a brief mid-life CASIN pulse was associated approximately 11 months later with long-term attenuation of age-associated skeletal degeneration, accompanied by coordinated changes across the mesenchymal osteogenic and HSC-derived myeloid/osteoclast lineages. Direct cytoskeletal and mitochondrial evidence was obtained in MSPCs, whereas the hematopoietic and osteoclast findings indicate broader multi-lineage effects. These data identify CDC42-sensitive responses across the two major stem-cell-derived compartments of the bone marrow as a potential determinant of skeletal aging.
- Open Access
- 6 July 2026
- Published by Springer Nature in Bone Research
- Vol. 14 (1) , 71
Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass
Osteoporosis, a prevalent age-related disease, is characterized by impaired bone formation and an increased risk of fractures. Current anabolic treatments primarily rely on biologics, which are costly and require inconvenient administration. Identifying regulators of osteoblastogenesis that are amenable to small-molecule targeting is essential for developing more accessible therapies. Through an unbiased kinome-wide RNAi screen in primary murine calvarial osteoblasts, we identified the AXL receptor tyrosine kinase (Axl) as a negative regulator of osteoblast differentiation. Axl is most highly expressed in undifferentiated and early differentiated osteoblasts, with a rapid decline in expression during osteoblast maturation. siRNA-mediated knockdown of Axl or pharmacological inhibition with the small molecule BGB324 significantly enhanced osteoblast differentiation and mineralization in vitro. In mice, BGB324 treatment significantly increased bone mass by promoting bone formation. Mechanistically, Axl knockdown or inhibition upregulated interferon-stimulated gene 15 (Isg15) , while Isg15 knockdown impaired osteoblast differentiation and enhanced Erk phosphorylation, leading to increased expression of osteoblast-specific genes. Consistently, double knockdown experiments demonstrated that simultaneous loss of Axl with either Isg15 or Mapk1 , but not other interferon-related genes, reversed the Axl knockdown-induced increase in osteoblast differentiation, reinforcing their mechanistic involvement. Collectively, our study identifies Axl as a promising therapeutic target for osteoporosis and other bone-related disorders.
- 6 July 2026
- Published by Springer Nature in Bone Research
- Vol. 14 (1) , 71
Open AccessInhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass
Osteoporosis, a prevalent age-related disease, is characterized by impaired bone formation and an increased risk of fractures. Current anabolic treatments primarily rely on biologics, which are costly and require inconvenient administration. Identifying regulators of osteoblastogenesis that are amenable to small-molecule targeting is essential for developing more accessible therapies. Through an unbiased kinome-wide RNAi screen in primary murine calvarial osteoblasts, we identified the AXL receptor tyrosine kinase (Axl) as a negative regulator of osteoblast differentiation. Axl is most highly expressed in undifferentiated and early differentiated osteoblasts, with a rapid decline in expression during osteoblast maturation. siRNA-mediated knockdown of Axl or pharmacological inhibition with the small molecule BGB324 significantly enhanced osteoblast differentiation and mineralization in vitro. In mice, BGB324 treatment significantly increased bone mass by promoting bone formation. Mechanistically, Axl knockdown or inhibition upregulated interferon-stimulated gene 15 (Isg15) , while Isg15 knockdown impaired osteoblast differentiation and enhanced Erk phosphorylation, leading to increased expression of osteoblast-specific genes. Consistently, double knockdown experiments demonstrated that simultaneous loss of Axl with either Isg15 or Mapk1 , but not other interferon-related genes, reversed the Axl knockdown-induced increase in osteoblast differentiation, reinforcing their mechanistic involvement. Collectively, our study identifies Axl as a promising therapeutic target for osteoporosis and other bone-related disorders.
- Open Access
- 27 September 2023
- Published by Springer Nature in Bone Research
- Vol. 11 (1) , 1-14
Loss of Notch signaling in skeletal stem cells enhances bone formation with aging
Skeletal stem and progenitor cells (SSPCs) perform bone maintenance and repair. With age, they produce fewer osteoblasts and more adipocytes leading to a loss of skeletal integrity. The molecular mechanisms that underlie this detrimental transformation are largely unknown. Single-cell RNA sequencing revealed that Notch signaling becomes elevated in SSPCs during aging. To examine the role of increased Notch activity, we deleted Nicastrin, an essential Notch pathway component, in SSPCs in vivo. Middle-aged conditional knockout mice displayed elevated SSPC osteo-lineage gene expression, increased trabecular bone mass, reduced bone marrow adiposity, and enhanced bone repair. Thus, Notch regulates SSPC cell fate decisions, and moderating Notch signaling ameliorates the skeletal aging phenotype, increasing bone mass even beyond that of young mice. Finally, we identified the transcription factor Ebf3 as a downstream mediator of Notch signaling in SSPCs that is dysregulated with aging, highlighting it as a promising therapeutic target to rejuvenate the aged skeleton.
- 27 September 2023
- Published by Springer Nature in Bone Research
- Vol. 11 (1) , 1-14
Open AccessLoss of Notch signaling in skeletal stem cells enhances bone formation with aging
Skeletal stem and progenitor cells (SSPCs) perform bone maintenance and repair. With age, they produce fewer osteoblasts and more adipocytes leading to a loss of skeletal integrity. The molecular mechanisms that underlie this detrimental transformation are largely unknown. Single-cell RNA sequencing revealed that Notch signaling becomes elevated in SSPCs during aging. To examine the role of increased Notch activity, we deleted Nicastrin, an essential Notch pathway component, in SSPCs in vivo. Middle-aged conditional knockout mice displayed elevated SSPC osteo-lineage gene expression, increased trabecular bone mass, reduced bone marrow adiposity, and enhanced bone repair. Thus, Notch regulates SSPC cell fate decisions, and moderating Notch signaling ameliorates the skeletal aging phenotype, increasing bone mass even beyond that of young mice. Finally, we identified the transcription factor Ebf3 as a downstream mediator of Notch signaling in SSPCs that is dysregulated with aging, highlighting it as a promising therapeutic target to rejuvenate the aged skeleton.
- Open Access
- 6 April 2022
- Published by Springer Nature in Bone Research
- Vol. 10 (1) , 1-13
Inhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing
Identification of regulators of osteoblastogenesis that can be pharmacologically targeted is a major goal in combating osteoporosis, a common disease of the elderly population. Here, unbiased kinome RNAi screening in primary murine osteoblasts identified cyclin-dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation in both murine and human preosteoblastic cells. Cdk5 knockdown by siRNA, genetic deletion using the Cre-loxP system, or inhibition with the small molecule roscovitine enhanced osteoblastogenesis in vitro. Roscovitine treatment significantly enhanced bone mass by increasing osteoblastogenesis and improved fracture healing in mice. Mechanistically, downregulation of Cdk5 expression increased Erk phosphorylation, resulting in enhanced osteoblast-specific gene expression. Notably, simultaneous Cdk5 and Erk depletion abrogated the osteoblastogenesis conferred by Cdk5 depletion alone, suggesting that Cdk5 regulates osteoblast differentiation through MAPK pathway modulation. We conclude that Cdk5 is a potential therapeutic target to treat osteoporosis and improve fracture healing.
- 6 April 2022
- Published by Springer Nature in Bone Research
- Vol. 10 (1) , 1-13
Open AccessInhibition of Cdk5 increases osteoblast differentiation and bone mass and improves fracture healing
Identification of regulators of osteoblastogenesis that can be pharmacologically targeted is a major goal in combating osteoporosis, a common disease of the elderly population. Here, unbiased kinome RNAi screening in primary murine osteoblasts identified cyclin-dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation in both murine and human preosteoblastic cells. Cdk5 knockdown by siRNA, genetic deletion using the Cre-loxP system, or inhibition with the small molecule roscovitine enhanced osteoblastogenesis in vitro. Roscovitine treatment significantly enhanced bone mass by increasing osteoblastogenesis and improved fracture healing in mice. Mechanistically, downregulation of Cdk5 expression increased Erk phosphorylation, resulting in enhanced osteoblast-specific gene expression. Notably, simultaneous Cdk5 and Erk depletion abrogated the osteoblastogenesis conferred by Cdk5 depletion alone, suggesting that Cdk5 regulates osteoblast differentiation through MAPK pathway modulation. We conclude that Cdk5 is a potential therapeutic target to treat osteoporosis and improve fracture healing.
- Open Access
- 8 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 404
Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice
Glucocorticoids (GCs) are widely used to treat inflammatory diseases. However, their long-term use leads to glucocorticoid-induced osteoporosis, increasing morbidity and mortality. Both anabolic and anti-resorptive drugs are used to counteract GC-induced bone loss, however, they are expensive and/or have major side effects. Therefore, identifying new targets for cost-effective, small-molecule inhibitors is essential. We recently identified cyclin-dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation and showed that its inhibition with roscovitine promoted osteoblastogenesis, thus improving the skeletal bone mass and fracture healing. Here, we assessed whether Cdk5 knockdown or inhibition could also reverse the GC-mediated suppression of osteoblast differentiation, bone loss, and fracture healing. We first demonstrated that Cdk5 silencing abolished the dexamethasone (Dex)-induced downregulation of alkaline phosphatase (Alp) activity, osteoblast-specific marker gene expression (Runx2, Sp7, Alpl, and Bglap), and mineralization. Similarly, Cdk5 inhibition rescued Dex-induced suppression of Alp activity. We further demonstrated that Cdk5 inhibition reversed prednisolone (Pred)-induced bone loss in mice, due to reduced osteoclastogenesis rather than improved osteoblastogenesis. Moreover, we revealed that Cdk5 inhibition failed to improve Pred-mediated impaired fracture healing. Taken together, we demonstrated that Cdk5 inhibition with roscovitine ameliorated GC-mediated bone loss but did not reverse GC-induced compromised fracture healing in mice.
- 8 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 404
Open AccessInhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice
Glucocorticoids (GCs) are widely used to treat inflammatory diseases. However, their long-term use leads to glucocorticoid-induced osteoporosis, increasing morbidity and mortality. Both anabolic and anti-resorptive drugs are used to counteract GC-induced bone loss, however, they are expensive and/or have major side effects. Therefore, identifying new targets for cost-effective, small-molecule inhibitors is essential. We recently identified cyclin-dependent kinase 5 (Cdk5) as a suppressor of osteoblast differentiation and showed that its inhibition with roscovitine promoted osteoblastogenesis, thus improving the skeletal bone mass and fracture healing. Here, we assessed whether Cdk5 knockdown or inhibition could also reverse the GC-mediated suppression of osteoblast differentiation, bone loss, and fracture healing. We first demonstrated that Cdk5 silencing abolished the dexamethasone (Dex)-induced downregulation of alkaline phosphatase (Alp) activity, osteoblast-specific marker gene expression (Runx2, Sp7, Alpl, and Bglap), and mineralization. Similarly, Cdk5 inhibition rescued Dex-induced suppression of Alp activity. We further demonstrated that Cdk5 inhibition reversed prednisolone (Pred)-induced bone loss in mice, due to reduced osteoclastogenesis rather than improved osteoblastogenesis. Moreover, we revealed that Cdk5 inhibition failed to improve Pred-mediated impaired fracture healing. Taken together, we demonstrated that Cdk5 inhibition with roscovitine ameliorated GC-mediated bone loss but did not reverse GC-induced compromised fracture healing in mice.
- Open Access
- 1 December 2019
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (5) , 932-941
Propranolol Reverses Impaired Fracture Healing Response Observed With Selective Serotonin Reuptake Inhibitor Treatment
Selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly prescribed antidepressants worldwide and recent data show significant impairment of fracture healing after treatment with the SSRI fluoxetine in mice. Here, we provide evidence that the negative effects of SSRIs can be overcome by administration of the beta-blocker propranolol at the time of fracture. First, in vitro experiments established that propranolol does not affect osteogenic differentiation. We then used a murine model of intramembranous ossification to study the potential rescue effect of propranolol on SSRI-induced impaired fracture healing. Micro-CT analysis revealed that fluoxetine treatment resulted in a smaller bony regenerate and that this decrease in bone formation can be overcome by co-treatment with propranolol. We then tested this in a clinically relevant model of endochondral ossification. Fluoxetine-treated mice with a femur fracture were treated with propranolol initiated at the time of fracture, and a battery of analyses demonstrated a reversal of the detrimental effect of fluoxetine on fracture healing in response to propranolol treatment. These experiments show for the first time to our knowledge that the negative effects of SSRIs on fracture healing can be overcome by co-treatment with a beta-blocker. © 2019 American Society for Bone and Mineral Research.
- 1 December 2019
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (5) , 932-941
Open AccessPropranolol Reverses Impaired Fracture Healing Response Observed With Selective Serotonin Reuptake Inhibitor Treatment
Selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly prescribed antidepressants worldwide and recent data show significant impairment of fracture healing after treatment with the SSRI fluoxetine in mice. Here, we provide evidence that the negative effects of SSRIs can be overcome by administration of the beta-blocker propranolol at the time of fracture. First, in vitro experiments established that propranolol does not affect osteogenic differentiation. We then used a murine model of intramembranous ossification to study the potential rescue effect of propranolol on SSRI-induced impaired fracture healing. Micro-CT analysis revealed that fluoxetine treatment resulted in a smaller bony regenerate and that this decrease in bone formation can be overcome by co-treatment with propranolol. We then tested this in a clinically relevant model of endochondral ossification. Fluoxetine-treated mice with a femur fracture were treated with propranolol initiated at the time of fracture, and a battery of analyses demonstrated a reversal of the detrimental effect of fluoxetine on fracture healing in response to propranolol treatment. These experiments show for the first time to our knowledge that the negative effects of SSRIs on fracture healing can be overcome by co-treatment with a beta-blocker. © 2019 American Society for Bone and Mineral Research.
- 20 March 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (14) , 6995-7004
Age-related inflammation triggers skeletal stem/progenitor cell dysfunction
Aging is associated with impaired tissue regeneration. Stem cell number and function have been identified as potential culprits. We first demonstrate a direct correlation between stem cell number and time to bone fracture union in a human patient cohort. We then devised an animal model recapitulating this age-associated decline in bone healing and identified increased cellular senescence caused by a systemic and local proinflammatory environment as the major contributor to the decline in skeletal stem/progenitor cell (SSPC) number and function. Decoupling age-associated systemic inflammation from chronological aging by using transgenic Nfkb1KO mice, we determined that the elevated inflammatory environment, and not chronological age, was responsible for the decrease in SSPC number and function. By using a pharmacological approach inhibiting NF-κB activation, we demonstrate a functional rejuvenation of aged SSPCs with decreased senescence, increased SSPC number, and increased osteogenic function. Unbiased, whole-genome RNA sequencing confirmed the reversal of the aging phenotype. Finally, in an ectopic model of bone healing, we demonstrate a functional restoration of regenerative potential in aged SSPCs. These data identify aging-associated inflammation as the cause of SSPC dysfunction and provide mechanistic insights into its reversal. Significance As we age, our capacity for tissue repair and regeneration in response to injury declines. Accordingly, bone repair is delayed and impaired in older patients. At the cornerstone of bone healing is the skeletal stem/progenitor cell (SSPC), whose function and number diminishes with age. However, the mechanisms driving this decline remain unclear. Here, we identify age-associated inflammation (“inflamm-aging”) as the main culprit of SSPC dysfunction and provide support for a central role of NF-κB as a mediator of inflamm-aging. Our results show that modification of the inflammatory environment may be a translational approach to functionally rejuvenate the aged SSPC, thereby improving the regenerative capacity of the aged skeleton.
- 20 March 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (14) , 6995-7004
Age-related inflammation triggers skeletal stem/progenitor cell dysfunction
Aging is associated with impaired tissue regeneration. Stem cell number and function have been identified as potential culprits. We first demonstrate a direct correlation between stem cell number and time to bone fracture union in a human patient cohort. We then devised an animal model recapitulating this age-associated decline in bone healing and identified increased cellular senescence caused by a systemic and local proinflammatory environment as the major contributor to the decline in skeletal stem/progenitor cell (SSPC) number and function. Decoupling age-associated systemic inflammation from chronological aging by using transgenic Nfkb1KO mice, we determined that the elevated inflammatory environment, and not chronological age, was responsible for the decrease in SSPC number and function. By using a pharmacological approach inhibiting NF-κB activation, we demonstrate a functional rejuvenation of aged SSPCs with decreased senescence, increased SSPC number, and increased osteogenic function. Unbiased, whole-genome RNA sequencing confirmed the reversal of the aging phenotype. Finally, in an ectopic model of bone healing, we demonstrate a functional restoration of regenerative potential in aged SSPCs. These data identify aging-associated inflammation as the cause of SSPC dysfunction and provide mechanistic insights into its reversal. Significance As we age, our capacity for tissue repair and regeneration in response to injury declines. Accordingly, bone repair is delayed and impaired in older patients. At the cornerstone of bone healing is the skeletal stem/progenitor cell (SSPC), whose function and number diminishes with age. However, the mechanisms driving this decline remain unclear. Here, we identify age-associated inflammation (“inflamm-aging”) as the main culprit of SSPC dysfunction and provide support for a central role of NF-κB as a mediator of inflamm-aging. Our results show that modification of the inflammatory environment may be a translational approach to functionally rejuvenate the aged SSPC, thereby improving the regenerative capacity of the aged skeleton.
- 1 June 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (6) , 1061-1077.e6
Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling
- 1 June 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (6) , 1061-1077.e6
Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling
- 9 October 2017
- Published by Springer Nature in Oncogene
- Vol. 37 (5) , 616-626
Deletion of Menin in craniofacial osteogenic cells in mice elicits development of mandibular ossifying fibroma
Ossifying fibroma (OF) is a rare benign tumor of the craniofacial bones that can reach considerable and disfiguring dimensions if left untreated. Although the clinicopathological characteristics of OF are well established, the underlying etiology has remained largely unknown. Our work indicates that Men1—a tumor suppressor gene responsible of Multiple endocrine neoplasia type 1—is critical for OF formation and shows that mice with targeted disruption of Men1 in osteoblasts (Men1Runx2Cre) develop multifocal OF in the mandible with a 100% penetrance. Using lineage-tracing analysis, we demonstrate that loss of Men1 arrests stromal osteoprogenitors in OF at the osterix-positive pre-osteoblastic differentiation stage. Analysis of Men1-lacking stromal spindle cells isolated from OF (OF-derived MSCs (OFMSCs)) revealed a downregulation of the cyclin-dependent kinase (CDK) inhibitor Cdkn1a, consistent with an increased proliferation rate. Intriguingly, the re-expression of Men1 in Men1-deficient OFMSCs restored Cdkn1a expression and abrogated cellular proliferation supporting the tumor-suppressive role of Men1 in OF. Although our work presents the first evidence of Men1 in OF development, it further provides the first genetic mouse model of OF that can be used to better understand the molecular pathogenesis of these benign tumors and to potentially develop novel treatment strategies.
- 9 October 2017
- Published by Springer Nature in Oncogene
- Vol. 37 (5) , 616-626
Deletion of Menin in craniofacial osteogenic cells in mice elicits development of mandibular ossifying fibroma
Ossifying fibroma (OF) is a rare benign tumor of the craniofacial bones that can reach considerable and disfiguring dimensions if left untreated. Although the clinicopathological characteristics of OF are well established, the underlying etiology has remained largely unknown. Our work indicates that Men1—a tumor suppressor gene responsible of Multiple endocrine neoplasia type 1—is critical for OF formation and shows that mice with targeted disruption of Men1 in osteoblasts (Men1Runx2Cre) develop multifocal OF in the mandible with a 100% penetrance. Using lineage-tracing analysis, we demonstrate that loss of Men1 arrests stromal osteoprogenitors in OF at the osterix-positive pre-osteoblastic differentiation stage. Analysis of Men1-lacking stromal spindle cells isolated from OF (OF-derived MSCs (OFMSCs)) revealed a downregulation of the cyclin-dependent kinase (CDK) inhibitor Cdkn1a, consistent with an increased proliferation rate. Intriguingly, the re-expression of Men1 in Men1-deficient OFMSCs restored Cdkn1a expression and abrogated cellular proliferation supporting the tumor-suppressive role of Men1 in OF. Although our work presents the first evidence of Men1 in OF development, it further provides the first genetic mouse model of OF that can be used to better understand the molecular pathogenesis of these benign tumors and to potentially develop novel treatment strategies.
- Open Access
- 20 January 2017
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 24 (4) , 672-682
Loss of menin in osteoblast lineage affects osteocyte–osteoclast crosstalk causing osteoporosis
During osteoporosis bone formation by osteoblasts is reduced and/or bone resorption by osteoclasts is enhanced. Currently, only a few factors have been identified in the regulation of bone integrity by osteoblast-derived osteocytes. In this study, we show that specific disruption of menin, encoded by multiple endocrine neoplasia type 1 (Men1), in osteoblasts and osteocytes caused osteoporosis despite the preservation of osteoblast differentiation and the bone formation rate. Instead, an increase in osteoclast numbers and bone resorption was detected that persisted even when the deletion of Men1 was restricted to osteocytes. We demonstrate that isolated Men1-deficient osteocytes expressed numerous soluble mediators, such as C-X-C motif chemokine 10 (CXCL10), and that CXCL10-mediated osteoclastogenesis was reduced by CXCL10-neutralizing antibodies. Collectively, our data reveal a novel role for Men1 in osteocyte–osteoclast crosstalk by controlling osteoclastogenesis through the action of soluble factors. A role for Men1 in maintaining bone integrity and thereby preventing osteoporosis is proposed.
- 20 January 2017
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 24 (4) , 672-682
Open AccessLoss of menin in osteoblast lineage affects osteocyte–osteoclast crosstalk causing osteoporosis
During osteoporosis bone formation by osteoblasts is reduced and/or bone resorption by osteoclasts is enhanced. Currently, only a few factors have been identified in the regulation of bone integrity by osteoblast-derived osteocytes. In this study, we show that specific disruption of menin, encoded by multiple endocrine neoplasia type 1 (Men1), in osteoblasts and osteocytes caused osteoporosis despite the preservation of osteoblast differentiation and the bone formation rate. Instead, an increase in osteoclast numbers and bone resorption was detected that persisted even when the deletion of Men1 was restricted to osteocytes. We demonstrate that isolated Men1-deficient osteocytes expressed numerous soluble mediators, such as C-X-C motif chemokine 10 (CXCL10), and that CXCL10-mediated osteoclastogenesis was reduced by CXCL10-neutralizing antibodies. Collectively, our data reveal a novel role for Men1 in osteocyte–osteoclast crosstalk by controlling osteoclastogenesis through the action of soluble factors. A role for Men1 in maintaining bone integrity and thereby preventing osteoporosis is proposed.